BCL2 and neuroblastoma: Similarly, BH3 profiling was used to stratify neuroblastomas with a specific type of BCL-2 family-mediated resistance and thus facilitate in the prediction of neuroblastomas’ sensitivity towards different BCL-2 inhibitors.